Alfonso Galderisi1,2, Elise Schlissel3, Eda Cengiz4,5,6. 1. Division of Pediatric Endocrinology and Diabetes, Yale School of Medicine, 333 Cedar St., P.O. Box 208064, New Haven, CT, 06520, USA. 2. Department of Women and Children's Health, University of Padova, Padova, Italy. 3. Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA. 4. Division of Pediatric Endocrinology and Diabetes, Yale School of Medicine, 333 Cedar St., P.O. Box 208064, New Haven, CT, 06520, USA. Eda.Cengiz@yale.edu. 5. Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA. Eda.Cengiz@yale.edu. 6. Division of Pediatric Endocrinology, Koc University School of Medicine, Istanbul, Turkey. Eda.Cengiz@yale.edu.
Abstract
PURPOSE OF REVIEW: Decades after the invention of insulin pump, diabetes management has encountered a technology revolution with the introduction of continuous glucose monitoring, sensor-augmented insulin pump therapy and closed-loop/artificial pancreas systems. In this review, we discuss the significance of the 2016 Endocrine Society Guidelines for insulin pump therapy and continuous glucose monitoring and summarize findings from relevant diabetes technology studies that were conducted after the publication of the 2016 Endocrine Society Guidelines. RECENT FINDINGS: The 2016 Endocrine Society Guidelines have been a great resource for clinicians managing diabetes in this new era of diabetes technology. There is good body of evidence indicating that using diabetes technology systems safely tightens glycemic control while managing both type 1 and type 2 diabetes. The first-generation diabetes technology systems will evolve as we gain more experience and collaboratively work to improve them with an ultimate goal of keeping people with diabetes complication and burden-free until the cure for diabetes becomes a reality.
PURPOSE OF REVIEW: Decades after the invention of insulin pump, diabetes management has encountered a technology revolution with the introduction of continuous glucose monitoring, sensor-augmented insulin pump therapy and closed-loop/artificial pancreas systems. In this review, we discuss the significance of the 2016 Endocrine Society Guidelines for insulin pump therapy and continuous glucose monitoring and summarize findings from relevant diabetes technology studies that were conducted after the publication of the 2016 Endocrine Society Guidelines. RECENT FINDINGS: The 2016 Endocrine Society Guidelines have been a great resource for clinicians managing diabetes in this new era of diabetes technology. There is good body of evidence indicating that using diabetes technology systems safely tightens glycemic control while managing both type 1 and type 2 diabetes. The first-generation diabetes technology systems will evolve as we gain more experience and collaboratively work to improve them with an ultimate goal of keeping people with diabetes complication and burden-free until the cure for diabetes becomes a reality.
Entities:
Keywords:
Continuous glucose monitoring; Hybrid closed-loop; Insulin pump; Type 1 diabetes; Type 2 diabetes
Authors: Anne L Peters; Andrew J Ahmann; Tadej Battelino; Alison Evert; Irl B Hirsch; M Hassan Murad; William E Winter; Howard Wolpert Journal: J Clin Endocrinol Metab Date: 2016-09-02 Impact factor: 5.958
Authors: Roy W Beck; Tonya Riddlesworth; Katrina Ruedy; Andrew Ahmann; Richard Bergenstal; Stacie Haller; Craig Kollman; Davida Kruger; Janet B McGill; William Polonsky; Elena Toschi; Howard Wolpert; David Price Journal: JAMA Date: 2017-01-24 Impact factor: 56.272
Authors: Curtiss B Cook; Karen A Beer; Karen M Seifert; Mary E Boyle; Patricia A Mackey; Janna C Castro Journal: J Diabetes Sci Technol Date: 2012-09-01
Authors: Scott M Blackman; Dan Raghinaru; Saleh Adi; Jill H Simmons; Laurie Ebner-Lyon; H Peter Chase; William V Tamborlane; Desmond A Schatz; Jennifer M Block; Jean C Litton; Vandana Raman; Nicole C Foster; Craig R Kollman; Stephanie N DuBose; Kellee M Miller; Roy W Beck; Linda A DiMeglio Journal: Pediatr Diabetes Date: 2014-02-04 Impact factor: 4.866
Authors: Richard M Bergenstal; David C Klonoff; Satish K Garg; Bruce W Bode; Melissa Meredith; Robert H Slover; Andrew J Ahmann; John B Welsh; Scott W Lee; Francine R Kaufman Journal: N Engl J Med Date: 2013-06-22 Impact factor: 91.245
Authors: Bruce A Buckingham; Dan Raghinaru; Fraser Cameron; B Wayne Bequette; H Peter Chase; David M Maahs; Robert Slover; R Paul Wadwa; Darrell M Wilson; Trang Ly; Tandy Aye; Irene Hramiak; Cheril Clarson; Robert Stein; Patricia H Gallego; John Lum; Judy Sibayan; Craig Kollman; Roy W Beck Journal: Diabetes Care Date: 2015-06-06 Impact factor: 19.112